Akari Therapeutics Plc 1Q 2026: Net income $(14.5M), EPS $(0.00) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.
Akari Therapeutics Plc reported a net loss of $(14.5M) in Q1 2026, widening from $(3.7M) in Q1 2025, with no product sales as the company remains pre-revenue. Diluted EPS was $(0.00) for both quarters. The company initiated GMP manufacturing for AKTX-101 and is focusing on its PH1-based ADC platform. An ASCO 2026 abstract was accepted for research on KRAS-mutated pancreatic cancer.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments